Drug agency Cadila Healthcare on Friday stated it has entered into an settlement with Shilpa Medicare for the manufacturing of its COVID-19 vaccine, ZyCoV-D.
The firm, “through its wholly owned subsidiary, Shilpa Biologicals, has entered into a definitive agreement with Shilpa Medicare for the production of ZyCoV-D vaccine drug substance from its Integrated Biologics R&D co-manufacturing center in Dharwad, Karnataka- is for supply,” Cadila Healthcare stated in a regulatory submitting.
This facility will mutually agree on the focused manufacturing of the ZyCoV-D vaccine.
“The company will transfer the ZyCoV-D technology to Shilpa Biologicals Private Limited (SBPL). Under the agreement, SBPL will be responsible for manufacturing the pharmaceutical substance of the vaccine, while the company is responsible for filling/packaging/distributing/marketing the vaccine in its marketing areas,” stated Cadila Healthcare.
ZyCoV-D is the world’s first DNA plasmid vaccine for human use, indigenously developed by the corporate towards the COVID-19 virus.
The vaccine was granted Emergency Use Authorization (EUA) by the Indian drug regulator on 20 August.
Shares of Cadila Healthcare have been buying and selling at Rs 564.30 per share on the BSE, down 0.46 per cent from the earlier shut.
With inputs from TheIndianEXPRESS